- Home
- MRCC vs CNTB Comparison
MRCC vs CNTB Comparison
Compare MRCC & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | CNTB |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 128.6M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRCC | CNTB |
|---|---|---|
| Price | $4.76 | $2.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 142.0K | 107.6K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 7.81% | N/A |
| EPS Growth | N/A | ★ 75.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,033,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,617.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.11 | $0.51 |
| 52 Week High | $7.92 | $3.28 |
Technical Indicators
Market Signals| Indicator | MRCC | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 52.08 |
| Support Level | $4.11 | $2.09 |
| Resistance Level | $6.91 | $2.86 |
| Average True Range (ATR) | 0.32 | 0.20 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 31.35 | 47.76 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.